Navigation Links
Genome Quebec and Montreal Heart Institute Pharmacogenomics Centre Deploys Isilon IQ in Next Generation of Drug Development
Date:10/5/2009

SEATTLE, Oct. 5 /PRNewswire-FirstCall/ -- Isilon® Systems (Nasdaq: ISLN), the proven leader in scale-out NAS, today announced that Pharmacogenomics Centre, a partnership between Genome Quebec and the Montreal Heart Institute focused on enhancing new and existing drug development research programs through the inclusion of genetic information, has deployed Isilon IQ to accelerate its next-generation genetic sequencing operations. In its focused efforts to fight heart disease, cancer and other life-threatening diseases, Pharmacogenomics Centre is leveraging Isilon scale-out NAS to significantly increase workflow efficiency and productivity, while reducing storage management from more than 30 hours per week to less than one hour per week.

"We're sequencing targeted segments of patients' DNA to try and identify individual mutations that can cause those patients to respond unexpectedly to specific drug therapies," said Christopher Beck, senior bioinformatician, Pharmacogenomics Centre. "Obviously the data produced by our next-generation sequencers is mission-critical but we are a scientific organization and our main focus is data analysis, not data storage. We simply can't afford the lengthy storage deployment schedules or complex system management hassles that traditional storage offerings require. With Isilon, we've been able to deploy and manage a high-performance, highly scalable, shared storage resource without having to dedicate any IT staff to managing the system."

With Isilon scale-out NAS, Pharmacogenomics Centre has unified both its DNA sequencing and DNA analysis operations onto a single, shared pool of storage, enabling highly concurrent processing of genomic data to increase productivity and speed time-to-results. Additionally, with Isilon's OneFS® operating system providing 'pay as you grow' scalability, Pharmacogenomics Centre can scale both performance and capacity on-demand to meet the dramatic and unpredictable growth of data within its high-throughput sequencing environment.

"Next-generation genetics research is opening entirely new ways of undertaking critical drug discovery research," said Chris Blessington, senior director of marketing and communications, Isilon Systems. "Pharamcogenomics Centre's successful use of Isilon IQ to advance this new era of drug development is demonstrative of the inherent performance, capacity, and manageability advantages of our scale-out NAS solutions for data-rich life sciences organizations."

About Isilon Systems

Isilon Systems (Nasdaq: ISLN) is the proven leader in scale-out NAS. Isilon's clustered storage and data management solutions drive unique business value for customers by maximizing the performance of their mission-critical applications, workflows, and processes. Isilon enables enterprises and research organizations worldwide to manage large and rapidly growing amounts of file-based data in a highly scalable, easy-to-manage, and cost-effective way. Information about Isilon can be found at http://www.isilon.com.

The names of companies mentioned herein are the trademarks of their respective owners.

SOURCE Isilon Systems


'/>"/>
SOURCE Isilon Systems
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
2. FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSKs Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight
3. Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)
4. First Jatropha Genome Completed by Synthetic Genomics Inc. and Asiatic Centre for Genome Technology
5. Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
6. Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
7. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
8. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
9. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
10. Breakthrough Mapping of Alzheimers Genome Helps ID Four New Suspect Genes
11. Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... YORK , Jan. 23, 2017 ... detect, and control light. The interaction of these ... used in a wide range of applications. These ... aerospace and defense, telecommunications, and healthcare among others. ... primarily owing to its low power consumption, reliability, ...
(Date:1/24/2017)... VALLEY COTTAGE, New York , January 23, 2017 ... Projected to Witness Sluggish Growth ... world are derived from formulating Active Pharmaceutical Ingredients (API), ... isopropanol, propanol and propylene glycol. Production of ... Asia-Pacific excluding Japan ...
(Date:1/23/2017)... 2017  Therabron Therapeutics, Inc., a clinical-stage biotechnology ... respiratory care, today announced that the European Medicines ... granted Orphan Drug Designation for Therabron,s CG367 program, ... (BOS).  "We are pleased to have ... treat patients diagnosed with BOS following lung transplantation. ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 23, 2017 , ... The Pharmacy and Medically Underserved ... bipartisan original co-sponsorship of nearly one-quarter of the U.S. House of Representatives. The ... Chain Drug Stores (NACDS) strongly backs the legislation. , “NACDS thanks for their ...
(Date:1/24/2017)... ... 23, 2017 , ... The TouchPoint Solution, parent company of ... into the product’s app. The data replicates and validates Co-Founder and Neuropsychologist ... 30 seconds of using Buzzies, people experienced a 74 percent reduction in their ...
(Date:1/23/2017)... York, NY (PRWEB) , ... January 23, 2017 , ... ... announced today that John J. Nelson, a senior accountant at the Firm, will participate ... of Make-A-Wish® Hudson Valley. Over 200 runners will race up 1,576 steps, a vertical ...
(Date:1/23/2017)... FL (PRWEB) , ... January 23, 2017 , ... Wooden and plastic balance boards have ... strength and improve balance. Kumo Board is the first and only balance board ... it to be soft and rigid at the same time as well as skill-level adjustable ...
(Date:1/23/2017)... ... 2017 , ... METTLER TOLEDO has announced the availability of ... PAT Tools . , Crystallization is a common step used during ... Chemists now spend more time developing better intermediate and final crystallization steps. ...
Breaking Medicine News(10 mins):